<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40946346</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-460X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of diabetes and its complications</Title><ISOAbbreviation>J Diabetes Complications</ISOAbbreviation></Journal><ArticleTitle>A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in China.</ArticleTitle><Pagination><StartPage>109174</StartPage><MedlinePgn>109174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdiacomp.2025.109174</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1056-8727(25)00227-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As a structurally unique peroxisome proliferator-activated receptor pan-agonist, chiglitazar has showed dual therapeutic benefits for glycemic control and lipid management in type 2 diabetes mellitus (T2DM). Despite these clinical advantages, comprehensive pharmacoeconomic evaluations comparing chiglitazar with conventional therapies like sitagliptin remain unavailable for China's healthcare system.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to conduct a comparative cost-utility analysis of chiglitazar versus sitagliptin for T2DM treatment in China, evaluating long-term clinical and economic outcomes from a healthcare system perspective.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data on patient demographics and post-treatment effects were collected from a double-blind, phase 3, randomized controlled trial conducted in China. The United Kingdom Prospective Diabetes Study Outcomes Model 2.1 was employed to evaluate the long-term effectiveness and associated costs. Uncertainties were addressed using one-way and probabilistic sensitivity analyses. Additionally, the binary search method was utilized to estimate an optimal annual cost for sitagliptin in scenario analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After a 40-year simulation, the life expectancy results were comparable among treatments: 14.93&#xa0;years for chiglitazar 32&#xa0;mg, 14.94&#xa0;years for chiglitazar 48&#xa0;mg, and 14.93&#xa0;years for sitagliptin 100&#xa0;mg. The corresponding quality-adjusted life years (QALYs) reached 12.82, 12.83, and 12.81, respectively. Total accumulated costs over the simulation period were $44,241.09 (chiglitazar 32&#xa0;mg), $45,044.25 (chiglitazar 48&#xa0;mg), and $44,821.45 (sitagliptin 100&#xa0;mg). Long-term economic evaluation revealed that chiglitazar 32&#xa0;mg provided the optimal cost-effectiveness, whereas sitagliptin 100&#xa0;mg was the least economically advantageous option. Both one-way and probabilistic sensitivity analyses confirmed the robustness of these findings. Scenario analysis showed that sitagliptin 100&#xa0;mg only becomes cost-effective when its annual cost is reduced by at least 42.33&#xa0;% compared to chiglitazar 32&#xa0;mg.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on cost-utility analysis within the Chinese healthcare context, chiglitazar demonstrates significantly better long-term health outcomes and cost-effectiveness relative to sitagliptin for T2DM management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zeyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong Province, 518001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhuoru</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong Province, 518001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Guimei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong Province, 518001, China. Electronic address: 13724349@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Weiling</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong Province, 518001, China. Electronic address: 752557163@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Diabetes Complications</MedlineTA><NlmUniqueID>9204583</NlmUniqueID><ISSNLinking>1056-8727</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chiglitazar</Keyword><Keyword MajorTopicYN="N">Cost-utility analysis</Keyword><Keyword MajorTopicYN="N">Sitagliptin</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes mellitus</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>18</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>18</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>17</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40946346</ArticleId><ArticleId IdType="doi">10.1016/j.jdiacomp.2025.109174</ArticleId><ArticleId IdType="pii">S1056-8727(25)00227-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>